Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

CAPVAXIVE SOLUTION FOR INJECTION [SIN17471P]

Active ingredients: CAPVAXIVE SOLUTION FOR INJECTION

View product's general information
Last updated 24 April 2026

Product Info

CAPVAXIVE SOLUTION FOR INJECTION

[SIN17471P]

Product information

Active Ingredient and Strength

(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15A CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 16F CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20A CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23A CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23B CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 24F CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 31 CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 35B CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8 CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N CONJUGATED TO CRM197 - 4 MCG/0.5 ML
(MBC) PNEUMOCOCCAL POLYSACCHARIDE DE-O-ACETYLATED SEROTYPE 15B CONJUGATED TO CRM197 - 4 MCG/0.5 ML

Dosage Form

INJECTION, SOLUTION

Manufacturer and Country

MSD INTERNATIONAL GMBH - IRELAND

Registration Number

SIN17471P

Licence Holder

MSD PHARMA (SINGAPORE) PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

J07AL02

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

1. INDICATIONS AND USAGE

CAPVAXIVE is indicated for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) in adults 18 years of age and older.

CAPVAXIVE will only protect against S. pneumoniae serotypes as indicated above.

CAPVAXIVE should be used in accordance with official recommendations.

Dosing

2. DOSAGE AND ADMINISTRATION

2.1 General
Dosage
Administer a single 0.5 mL dose of CAPVAXIVE intramuscularly.

Method of Administration
For intramuscular injection only. Do not inject intravascularly.

2.2 Adults
One single dose.

2.3 Vaccination of Individuals Previously Vaccinated with One or More Doses of Other Pneumococcal Vaccines
Administer a single dose of CAPVAXIVE to adults 18 years of age and older previously vaccinated with one or more doses of other pneumococcal vaccines. The dose of CAPVAXIVE should be administered at least 8 weeks after the last dose of the prior pneumococcal vaccine.

Contraindications

4. CONTRAINDICATIONS

CAPVAXIVE is contraindicated in individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine including diphtheria toxoid. [See Pharmaceutical Particulars (15.2) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.]